PeptiDream (4587) Aktienübersicht
PeptiDream Inc. ist ein biopharmazeutisches Unternehmen, das sich mit der Entdeckung und Entwicklung von gebundenen Peptiden, kleinen Molekülen und Peptid-Wirkstoff-Konjugaten beschäftigt. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 4/6 |
| Künftiges Wachstum | 4/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 3/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
Bei unseren Risikoprüfungen wurden keine Risiken für 4587 festgestellt.
4587 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
PeptiDream Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | JP¥1,215.50 |
| 52-Wochen-Hoch | JP¥1,818.50 |
| 52-Wochen-Tief | JP¥1,058.50 |
| Beta | 0.17 |
| 1 Monat Veränderung | 8.04% |
| 3 Monate Veränderung | -10.53% |
| 1 Jahr Veränderung | -27.37% |
| 3 Jahre Veränderung | -36.09% |
| 5 Jahre Veränderung | -76.12% |
| Veränderung seit IPO | 69.11% |
Aktuelle Nachrichten und Updates
4587: Out Licensing Progress And Autoimmune Pipeline Will Support Future Upside
Analysts have trimmed their price target on PeptiDream to ¥1,600 from ¥2,600, citing slower than expected progress in product out licensing and adjustments to fair value, discount rate, revenue growth, profit margin and future P/E assumptions. Analyst Commentary Bearish analysts are flagging that the lower ¥1,600 price target reflects reduced confidence in how quickly PeptiDream can execute on its product out licensing plans and convert its pipeline into revenue.
4587: Out Licensing Milestones Will Eventually Support Stronger Long Term Earnings Visibility
Analysts have reduced their price target on PeptiDream to ¥1,600 from ¥2,700, citing slower than expected progress in product out-licensing as the main reason for the adjustment. Analyst Commentary Bullish Takeaways Bullish analysts still see value at the revised price target of ¥1,600, arguing that expectations now better reflect the current pace of out-licensing activity.4587: Out Licensing Progress Will Support Stronger Long Term Earnings Visibility
Analysts have lowered their price target on PeptiDream to ¥2,825 from ¥3,008, citing slightly reduced fair value assumptions following slower than expected product out licensing, as reflected in updated discount rate, revenue growth, profit margin, and future P/E inputs. Analyst Commentary Recent research points to a more cautious stance on PeptiDream, with rating and target price adjustments linked mainly to timing risks around product out licensing.
4587: Out Licensing Progress And 2026 Earnings Targets Will Drive Future Upside
Analysts have modestly raised their fair value estimate for PeptiDream to ¥4,400 from ¥4,255, citing updated assumptions around discount rate, revenue growth, profit margin, and forward P/E, even as some have turned more cautious with a lower Street price target of ¥1,600 reflecting slower than expected product out licensing. Analyst Commentary Recent Street commentary highlights a mix of caution on timing of product out licensing and incremental confidence in PeptiDream's long term potential, reflected in the modest lift in fair value estimates despite a lower Street price target concentrated around ¥1,600.Recent updates
4587: Out Licensing Progress And Autoimmune Pipeline Will Support Future Upside
Analysts have trimmed their price target on PeptiDream to ¥1,600 from ¥2,600, citing slower than expected progress in product out licensing and adjustments to fair value, discount rate, revenue growth, profit margin and future P/E assumptions. Analyst Commentary Bearish analysts are flagging that the lower ¥1,600 price target reflects reduced confidence in how quickly PeptiDream can execute on its product out licensing plans and convert its pipeline into revenue.4587: Out Licensing Milestones Will Eventually Support Stronger Long Term Earnings Visibility
Analysts have reduced their price target on PeptiDream to ¥1,600 from ¥2,700, citing slower than expected progress in product out-licensing as the main reason for the adjustment. Analyst Commentary Bullish Takeaways Bullish analysts still see value at the revised price target of ¥1,600, arguing that expectations now better reflect the current pace of out-licensing activity.4587: Out Licensing Progress Will Support Stronger Long Term Earnings Visibility
Analysts have lowered their price target on PeptiDream to ¥2,825 from ¥3,008, citing slightly reduced fair value assumptions following slower than expected product out licensing, as reflected in updated discount rate, revenue growth, profit margin, and future P/E inputs. Analyst Commentary Recent research points to a more cautious stance on PeptiDream, with rating and target price adjustments linked mainly to timing risks around product out licensing.4587: Out Licensing Progress And 2026 Earnings Targets Will Drive Future Upside
Analysts have modestly raised their fair value estimate for PeptiDream to ¥4,400 from ¥4,255, citing updated assumptions around discount rate, revenue growth, profit margin, and forward P/E, even as some have turned more cautious with a lower Street price target of ¥1,600 reflecting slower than expected product out licensing. Analyst Commentary Recent Street commentary highlights a mix of caution on timing of product out licensing and incremental confidence in PeptiDream's long term potential, reflected in the modest lift in fair value estimates despite a lower Street price target concentrated around ¥1,600.4587: Oral Autoimmune Pipeline And siRNA Milestones Will Support Stronger Long Term Outlook
Analysts now set their PeptiDream price target at ¥3,008, down slightly from ¥3,033, reflecting updated assumptions around discount rate, revenue growth, profit margin, and future P/E. What's in the News PeptiDream issued consolidated earnings guidance for the fiscal year ending December 31, 2026, with expected revenue of ¥32,000 million, core operating profit and operating profit of ¥4,600 million, and profit attributable to owners of parent of ¥3,000 million (Corporate guidance).4587: Expanded Oral Pipeline And 2026 Milestones Will Drive Future Upside Potential
Analysts have slightly adjusted their price target on PeptiDream to ¥4,255 from ¥4,281 to reflect updated views on fair value, alongside refreshed assumptions for revenue growth, profit margin, discount rate and future P/E. What's in the News PeptiDream issued consolidated earnings guidance for the fiscal year ending December 31, 2026, expecting revenue of ¥32,000 million, core operating profit and operating profit of ¥4,600 million, and profit attributable to owners of parent of ¥3,000 million.Analysts Have Lowered Expectations For PeptiDream Inc. (TSE:4587) After Its Latest Results
There's been a notable change in appetite for PeptiDream Inc. ( TSE:4587 ) shares in the week since its yearly report...4587: Oral Autoimmune Pipeline Progress Will Drive Stronger Long Term Outlook
Analysts have trimmed their price target on PeptiDream to reflect a fair value of ¥3,033, down from ¥3,271, as they factor in slightly softer revenue growth and profit margin assumptions, along with a modestly higher discount rate and P/E multiple outlook. What's in the News PeptiDream reported a revision to its fiscal year 2025 guidance, now expecting revenue of ¥18,000 million instead of ¥49,000 million, with an operating loss of ¥5,400 million and a loss attributable to owners of parent of ¥4,000 million, citing delays in anticipated milestones and partnering deals including its oral myostatin program.4587: Milestone Progress In RNAi Delivery Platform Will Support Future Upside
Analysts now mark their fair value estimate for PeptiDream at ¥2,600, up from ¥2,500, reflecting adjustments to discount rates, revenue growth assumptions, profit margins, and a higher future P/E multiple. What's in the News PeptiDream reported a preclinical development milestone in its collaboration with Alnylam Pharmaceuticals, supporting a modular platform for precision siRNA delivery using macrocyclic peptides to target organs beyond the liver, with associated milestone payments and potential future royalties from Alnylam products (Key Developments).4587: Expanded Pipeline Milestones Will Drive Future Upside Potential
Analysts have reduced their price expectations for PeptiDream, reflecting updated assumptions for slightly lower revenue growth and profit margins, along with a higher future P/E multiple. Together, these changes reduce the implied upside from prior targets on a discounted cash flow basis.4587: Rebound In Partnering Revenues Will Drive Strong Upside Potential
Analysts have trimmed their price target on PeptiDream from ¥4,830 to ¥4,281, reflecting a slightly higher discount rate, even as they modestly raise long term revenue growth and profit margin assumptions and apply a lower future P E multiple. What's in the News PeptiDream sharply cut its FY25 revenue guidance to JPY 18 billion from JPY 49 billion, and now expects an operating loss of JPY 5.4 billion instead of a JPY 21.6 billion profit, as milestone and partnering revenues shift into FY26 (company guidance).This Just In: Analysts Are Boosting Their PeptiDream Inc. (TSE:4587) Outlook for Next Year
Shareholders in PeptiDream Inc. ( TSE:4587 ) may be thrilled to learn that the analysts have just delivered a major...4587: Radiopharmaceutical Pipeline Progress Will Drive Stronger Long Term Outlook
Analysts have modestly reduced their price target on PeptiDream from ¥3,414 to ¥3,271 as they incorporate a slightly higher discount rate, even as they update their assumptions to reflect stronger revenue growth, improved profitability, and a lower future P/E multiple. What's in the News PeptiDream, PDRadiopharma, and Curium have initiated a registrational Phase 2 clinical trial in Japan for 64Cu-PSMA-I&T, a PET radiopharmaceutical targeting PSMA expressed on prostate cancer cells (Key Developments).Is PeptiDream (TSE:4587) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...AI Discovery And Peptide Pipeline Will Expand Horizons
With both the discount rate and future P/E multiple showing only negligible movement, there has been no material change to PeptiDream's consensus analyst fair value, which remains steady at ¥3414. Valuation Changes Summary of Valuation Changes for PeptiDream The Consensus Analyst Price Target remained effectively unchanged, at ¥3414.PeptiDream (TSE:4587) Seems To Use Debt Rather Sparingly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Here's Why We Think PeptiDream (TSE:4587) Might Deserve Your Attention Today
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Advancements In Radiopharmaceutical Pipeline And Novartis Deal Will Drive Future Success
Expansion of deals and strategic partnerships positions PeptiDream for substantial future revenue growth from clinical advancements and imaging collaborations.PeptiDream (TSE:4587) Has A Rock Solid Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Bullish: Analysts Just Made A Decent Upgrade To Their PeptiDream Inc. (TSE:4587) Forecasts
Shareholders in PeptiDream Inc. ( TSE:4587 ) may be thrilled to learn that the analysts have just delivered a major...Earnings Miss: PeptiDream Inc. Missed EPS By 5.6% And Analysts Are Revising Their Forecasts
It's been a pretty great week for PeptiDream Inc. ( TSE:4587 ) shareholders, with its shares surging 18% to JP¥2,328 in...PeptiDream Inc.'s (TSE:4587) Price Is Out Of Tune With Earnings
When close to half the companies in Japan have price-to-earnings ratios (or "P/E's") below 13x, you may consider...Are Investors Undervaluing PeptiDream Inc. (TSE:4587) By 39%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, PeptiDream fair value estimate is JP¥4,230 PeptiDream is...PeptiDream's (TSE:4587) Performance Is Even Better Than Its Earnings Suggest
Even though PeptiDream Inc.'s ( TSE:4587 ) recent earnings release was robust, the market didn't seem to notice...PeptiDream Inc. Just Missed Earnings; Here's What Analysts Are Forecasting Now
It's been a good week for PeptiDream Inc. ( TSE:4587 ) shareholders, because the company has just released its latest...Is PeptiDream (TSE:4587) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...PeptiDream Inc.'s (TSE:4587) Price Is Out Of Tune With Earnings
When close to half the companies in Japan have price-to-earnings ratios (or "P/E's") below 13x, you may consider...Do PeptiDream's (TSE:4587) Earnings Warrant Your Attention?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...PeptiDream Inc. (TSE:4587) Shares Could Be 37% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, PeptiDream fair value estimate is JP¥4,180 Current share price...PeptiDream Inc. Just Beat Revenue Estimates By 13%
Shareholders of PeptiDream Inc. ( TSE:4587 ) will be pleased this week, given that the stock price is up 11% to...PeptiDream Inc. (TSE:4587) Surges 27% Yet Its Low P/S Is No Reason For Excitement
PeptiDream Inc. ( TSE:4587 ) shares have continued their recent momentum with a 27% gain in the last month alone...News Flash: Analysts Just Made A Meaningful Upgrade To Their PeptiDream Inc. (TSE:4587) Forecasts
Celebrations may be in order for PeptiDream Inc. ( TSE:4587 ) shareholders, with the analysts delivering a significant...PeptiDream Inc.'s (TSE:4587) 42% Price Boost Is Out Of Tune With Revenues
PeptiDream Inc. ( TSE:4587 ) shares have continued their recent momentum with a 42% gain in the last month alone...Is PeptiDream Inc. (TSE:4587) Trading At A 46% Discount?
Key Insights PeptiDream's estimated fair value is JP¥3,010 based on 2 Stage Free Cash Flow to Equity Current share...PeptiDream Inc.'s (TSE:4587) 25% Jump Shows Its Popularity With Investors
PeptiDream Inc. ( TSE:4587 ) shareholders would be excited to see that the share price has had a great month, posting a...Aktionärsrenditen
| 4587 | JP Biotechs | JP Markt | |
|---|---|---|---|
| 7D | 7.9% | -3.0% | 1.2% |
| 1Y | -27.4% | -11.3% | 42.1% |
Rendite im Vergleich zur Industrie: 4587 unter dem Niveau der Branche JP Biotechs , die im vergangenen Jahr eine Rendite von -11.3% erzielte.
Rendite vs. Markt: 4587 hinter dem Markt JP zurück, der im vergangenen Jahr eine Rendite von 42.1 erzielte.
Preisvolatilität
| 4587 volatility | |
|---|---|
| 4587 Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in JP Market | 9.6% |
| 10% least volatile stocks in JP Market | 2.5% |
Stabiler Aktienkurs: 4587 hatte in den letzten 3 Monaten im Vergleich zum JP -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: 4587Die wöchentliche Volatilität (7%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2006 | 645 | Patrick Crawford Reid | www.peptidream.com |
PeptiDream Inc. ist ein biopharmazeutisches Unternehmen, das sich mit der Entdeckung und Entwicklung von gebundenen Peptiden, kleinen Molekülen und Peptid-Wirkstoff-Konjugaten beschäftigt. Das Unternehmen entwickelt seine Produkte auf der Grundlage seines Peptide Discovery Platform System, einer Plattform zur Wirkstofffindung, die die Herstellung von nicht standardisierten Peptidbibliotheken zur Identifizierung potenter und selektiver makrozyklischer Peptidkandidaten ermöglicht, die dann zu Therapeutika und Diagnostika auf Peptidbasis, auf Basis kleiner Moleküle, Peptid-Wirkstoff-Konjugaten und multifunktionalen Peptidkonjugaten entwickelt werden können. Seine Entwicklungspipeline umfasst PD-L1, das für die Onkologie indiziert ist und sich derzeit in der klinischen Phase der Entwicklung befindet; PD-L1 BMS-986229, das für die Onkologie indiziert ist und sich derzeit in der klinischen Phase der Entwicklung befindet; CD38 BHV-1100 + NK-Zellen, das für das multiple Myelom indiziert ist und sich derzeit in der klinischen Phase der Entwicklung befindet; S2-Protein PA-001, das für COVID-19 indiziert ist und sich derzeit in der klinischen Phase der Entwicklung befindet; GhR AZP-3813, das für Akromegalie/NET indiziert ist und sich derzeit in der klinischen Phase der Entwicklung befindet; Glypican-3, das für Leberkrebs indiziert ist und sich derzeit in der präklinischen Entwicklungsphase befindet; Myostatin, das für DMD/Muskelerkrankungen indiziert ist und sich derzeit in der präklinischen Entwicklungsphase befindet; TfR, das für neuromuskuläre Erkrankungen indiziert ist und sich derzeit in der präklinischen Entwicklungsphase befindet; c-Kit, das für allergische Erkrankungen indiziert ist und sich derzeit in der präklinischen Entwicklungsphase befindet; c-Met, das sich derzeit in der präklinischen Entwicklungsphase befindet; und HA-Protein, das für Grippe indiziert ist und sich derzeit in der präklinischen Entwicklungsphase befindet.
PeptiDream Inc.'s Grundlagenzusammenfassung
| 4587 grundlegende Statistiken | |
|---|---|
| Marktanteil | JP¥157.06b |
| Gewinn(TTM) | -JP¥3.57b |
| Umsatz(TTM) | JP¥19.05b |
Ist 4587 zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| 4587 Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | JP¥19.05b |
| Kosten der Einnahmen | JP¥10.97b |
| Bruttogewinn | JP¥8.08b |
| Sonstige Ausgaben | JP¥11.65b |
| Gewinn | -JP¥3.57b |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -27.63 |
| Bruttomarge | 42.41% |
| Nettogewinnspanne | -18.74% |
| Schulden/Eigenkapital-Verhältnis | 32.8% |
Wie hat sich 4587 auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/23 23:05 |
| Aktienkurs zum Tagesende | 2026/05/22 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
PeptiDream Inc. wird von 14 Analysten beobachtet. 7 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Shan He | Bernstein |
| Hidemaru Yamaguchi | Citigroup Inc |
| Kazuaki Hashiguchi | Daiwa Securities Co. Ltd. |